Evotec SE stock (DE0005664809): Steady FY 2025 results amid US expansion
Published on 05/14/2026 at 19:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE, a leading provider of drug discovery and development services, published its fiscal year 2025 results on March 27, 2026, showing steady progress in key partnerships with pharmaceutical companies, according to Evotec IR as of 03/27/2026. The Hamburg-based firm continues to expand its US presence, appealing to American investors via its OTC listing. Shares traded at approximately 8.50 EUR on Xetra on May 13, 2026, according to ad-hoc-news.de as of 05/13/2026.
As of: 14.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Evotec SE
- Sector/industry: Biotechnology / Drug Discovery Services
- Headquarters/country: Hamburg, Germany
- Core markets: US, Europe
- Key revenue drivers: Integrated drug discovery, development partnerships
- Home exchange/listing venue: Xetra (EVT.DE)
- Trading currency: EUR
Official source
For first-hand information on Evotec SE, visit the company’s official website.
Go to the official websiteEvotec SE: core business model
Evotec SE operates an asset-agnostic drug discovery and development platform, partnering with big pharma and biotech companies to advance novel therapies. The company integrates industrial processes with technologies like AI-driven target identification and high-throughput screening. Headquartered in Hamburg, it employs over 5,000 scientists across sites in Europe and the US, including key facilities in Princeton, New Jersey.
Main revenue and product drivers for Evotec SE
Evotec SE generates revenue primarily through integrated drug discovery and development partnerships. These alliances with major pharmaceutical firms drive the bulk of income, as highlighted in the fiscal year 2025 results published on March 27, 2026, according to Evotec IR as of 03/27/2026. The firm's platform supports end-to-end services from target identification to clinical candidates.
Why Evotec SE matters for US investors
Evotec SE's OTC listing under EVTKY offers US investors direct access to a European biotech services leader without ADR complexities. With facilities in Princeton, New Jersey, the company taps into the US biotech outsourcing trend, providing exposure to pharma R&D spending amid domestic market volatility.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Conclusion
Evotec SE maintains operational resilience through diversified partnerships and US expansion, as shown in its fiscal year 2025 results from March 27, 2026. The stock's steady trading reflects a challenging yet opportunity-rich biotech environment. Investors track its role in global drug discovery for long-term trends.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
